Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money
On Jim Cramer’s “Mad Money” (June 30), he told a 23-year-old caller to buy Voyager Therapeutics (NASDAQ:VYGR) based on a long time horizon, noting the company is still unprofitable. Voyager has Q1 FY26 revenue of $2.59M (vs $8.79M consensus) and net loss of $27.94M; cash $171.66M. Analysts rate VYGR 11 Buys with ~$14.89–$15 average targets.
How this was made
The 30-second read
Why it matters
The piece combines (1) a qualitative endorsement based on investor age and (2) quantitative operating/cash and catalyst-calendar details, which can influence speculative positioning in VYGR around upcoming clinical milestones.
Market read
Traders may use the article’s specific catalyst window (IND clearance; first-in-human expected in 2H 2026) alongside dilution/cash-burn context to manage risk in a high-volatility pre-revenue biotech.
What to watch
The article emphasizes the Alzheimer’s “Year of Tau” narrative but provides limited detail on trial design, enrollment pace, and probability-weighted success assumptions that typically drive valuation for pre-revenue gene-therapy names.
Background
Jim Cramer comments on a 23-year-old caller’s long-horizon hold of Voyager Therapeutics, contrasting time-horizon tolerance with the company’s weak fundamentals.
Ticker impact
Voyager Therapeutics is discussed as a clinical-stage gene therapy firm, with Q1 FY26 revenue miss, cash runway, and 2026 Alzheimer’s dosing catalyst.
Near-term sentiment likely remains headline-driven (trial/catalyst calendar) while downside risk persists from cash burn, collaboration revenue decline, and the newly authorized share overhang.
It provides concrete operating datapoints (Q1 revenue miss, net loss, cash into 2028, collaboration revenue drop) plus a specific catalyst window (VY1706 IND clearance and first-in-human expected H2 2026), but the Cramer segment itself is not a new fundamental disclosure.
Market effects
Reinforces typical biotech/gene-therapy risk framing: pre-revenue cash runway, dilution overhang, and catalyst-calendar trading around IND/first dosing.
None material beyond US small-cap biotech sentiment.
Limited; primarily affects US-listed gene-therapy/Alzheimer’s speculative positioning.
Counterpoint
Even with dilution risk, the stated cash runway into 2028 and IND clearance could support a re-rating if investors treat H2 2026 first-in-human dosing as a near-term probability inflection.
Key entities
- companyVoyager Therapeutics
Clinical-stage gene therapy company; discussed with Q1 FY26 revenue miss, cash runway, and 2026 Alzheimer’s dosing catalyst timing.
- programVY1706
Alzheimer’s-related asset referenced as having IND clearance and expected first-in-human dosing in 2H 2026.
- partnerNeurocrine
Partnered program mentioned (Friedreich’s ataxia) with orphan drug designation and milestone potential.
- partnerNovartis
Collaboration revenue contributor referenced as deals matured and collaboration revenue declined.
